DiaMedica Therapeutics Inc. has entered into a Sales Agreement with TD Securities $(USA)$ LLC, commonly known as TD Cowen, allowing for the sale of its common shares up to an aggregate offering amount of $100 million. Under this agreement, shares may be sold at market offerings, as defined by the Securities Act of 1933. TD Cowen, acting as the sales agent, is not obligated to sell a specific number of shares but will use commercially reasonable efforts to facilitate the sales. The company has agreed to compensate TD Cowen with up to 3% of the gross proceeds from the sales, and will also cover certain costs and provide indemnification related to the sales process. This agreement marks a strategic move for DiaMedica to raise capital through public offerings, although no specific timeline or amount for the share sales has been disclosed.